Pozen news from FiercePharma
NewsGSK rebuked for missing Avandia reports
GlaxoSmithKline got a trip to the FDA woodshed for failing to regularly report post-marketing data it was gathering on the diabetes med Avandia. GSK failed to include updates on as many as 18 Read more...
| Press ReleasesPRSS RELEASE: Pozen, AstraZeneca Announce Start of the PN 400 Phase III Program POZEN/AstraZeneca Announce Start of the PN 400 Phase III Program AstraZeneca to Pay an Immediate $30 Million Payment Under Revised Licensing Arrangement CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Read more... |
Get more Pozen coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets